-
QL Biopharm Raises Series B Funding for Protein Drug Development
•
QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100 million (USD 14.46 million) in a Series B financing round. The round was led by Bluerun Ventures, with additional participation from Taizhou Pharmaceutical Hi-tech Zone Huayin Financial Investment, Lichen Private Equity Fund, and Mingfeng Capital.…
-
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for HB0025, an in-house developed bispecific antibody (BsAb) targeting programmed-death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF). The BsAb will be assessed in combination…
-
Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its adebrelimab (SHR-1316), a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb). The molecule is now approved for use in combination with chemotherapy to treat first-line extensive stage small-cell lung…
-
Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions
•
Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close to RMB 100 million (USD 14.46 million) in a Series A financing round. The round was led by Chengdu Tianfu International Bio-town’s fund, with additional contributions from Tao Capital. The proceeds will be directed towards…
-
Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its bevacizumab biosimilar. The approved indications for the biosimilar include the treatment of metastatic colorectal cancer (CRC), recurrent glioblastoma, and advanced metastatic or recurrent non-small cell lung cancer (NSCLC).…
-
Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing for its 9MW3911, a non-IL-2 blocking CD25 monoclonal antibody (mAb) developed via the high-efficiency B lymphocyte screening platform, has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication for this…
-
Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study
•
China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully enrolled in a confirmatory study in China for its Liwen RF ablation system, designed for the treatment of hypertrophic cardiomyopathy (HCM). This marks a significant step forward in the clinical development of this innovative device.…
-
PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices
•
PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by Kangju Venture Capital and Tsinghua Innovation Ventures. The proceeds will be directed towards clinical studies and the development of new product…
